专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20160166711A1 RABIES VACCINE 审中-公开
公开(公告)号：US20160166711A1
公开(公告)日：2016-06-16
申请号：US15048356
申请日：2016-02-19
申请人： CureVac AG
发明人： Margit SCHNEE , Thomas KRAMPS , Lothar STITZ , Benjamin PETSCH
IPC分类号： A61K48/00 , A61K9/00 , A61K39/42 , C12N7/00 , A61K39/205 , C07K14/005 , C07K16/10
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
摘要翻译：本发明涉及mRNA序列，其包含编码区，编码狂犬病病毒的至少一种抗原肽或蛋白质或其片段，变体或衍生物。另外，本发明涉及包含多个mRNA序列的组合物，其包含编码区域，编码狂犬病病毒的至少一种抗原肽或蛋白质或其片段，变体或衍生物。此外，它还公开了使用mRNA序列或包含多个mRNA序列的组合物用于制备药物组合物，特别是疫苗，例如疫苗。用于预防或治疗狂犬病病毒感染。本发明还描述了使用mRNA序列治疗或预防狂犬病的方法。

22. 发明申请

US20220211838A1 NUCLEIC ACID BASED COMBINATION VACCINES 有权
公开(公告)号：US20220211838A1
公开(公告)日：2022-07-07
申请号：US17665704
申请日：2022-02-07
申请人： CureVac AG
发明人： Cornelia OOSTVOGELS , Benjamin PETSCH , Susanne RAUCH , Kim Ellen SCHWENDT
IPC分类号： A61K39/145 , A61K39/155 , C07K14/005 , C12N7/00
摘要： The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

23. 发明申请

US20210260178A1 NOVEL LASSA VIRUS RNA MOLECULES AND COMPOSITIONS FOR VACCINATION 有权
公开(公告)号：US20210260178A1
公开(公告)日：2021-08-26
申请号：US17254847
申请日：2019-06-27
申请人： CureVac AG
发明人： Edith JASNY , Benjamin PETSCH , Hans Wolfgang GROSSE
IPC分类号： A61K39/12 , C07K14/005 , C12N7/00 , A61P31/14
摘要： The present invention is directed to RNA suitable for use in treatment and/or prophylaxis of an infection with Lassa virus (LASV) or of a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the RNA, compositions and vaccines.

24. 发明申请

US20210030866A1 VACCINATION IN NEWBORNS AND INFANTS 有权
公开(公告)号：US20210030866A1
公开(公告)日：2021-02-04
申请号：US17067709
申请日：2020-10-11
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Benjamin PETSCH , Lothar STITZ
IPC分类号： A61K39/155 , A61K39/12 , A61K39/145 , A61K47/59 , A61K47/64 , A61K47/69 , A61P31/16 , A61K39/00 , A61K45/06
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

25. 发明申请

US20210023199A1 VACCINATION WITH mRNA-CODED ANTIGENS 有权
公开(公告)号：US20210023199A1
公开(公告)日：2021-01-28
申请号：US17067614
申请日：2020-10-09
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Benjamin PETSCH , Lothar STITZ
IPC分类号： A61K39/145 , A61K39/12 , A61K39/00 , A61K45/06 , C12N7/00
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

26. 发明申请

US20200268908A1 RABIES VACCINE 审中-公开
公开(公告)号：US20200268908A1
公开(公告)日：2020-08-27
申请号：US16865107
申请日：2020-05-01
申请人： CureVac AG
发明人： Margit SCHNEE , Thomas KRAMPS , Lothar STITZ , Benjamin PETSCH
IPC分类号： A61K48/00 , A61K39/205 , A61K39/12 , A61K9/00 , A61K39/42 , C07K14/005 , C07K16/10 , C12N7/00
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.

27. 发明申请

US20190167782A1 VACCINATION IN NEWBORNS AND INFANTS 审中-公开
公开(公告)号：US20190167782A1
公开(公告)日：2019-06-06
申请号：US16273525
申请日：2019-02-12
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Benjamin PETSCH , Lothar STITZ
IPC分类号： A61K39/155 , A61K39/12 , A61K47/59 , A61K47/64 , A61K39/00 , A61K47/69 , A61P31/16 , A61K39/145 , A61K45/06
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

28. 发明申请

US20180312545A1 OPTIMIZED NUCLEIC ACID MOLECULES 审中-公开
公开(公告)号：US20180312545A1
公开(公告)日：2018-11-01
申请号：US15774423
申请日：2016-11-09
申请人： CureVac AG
发明人： Patrick BAUMHOF , Susanne RAUCH , Aleksandra KOWALCZYK , Johannes LUTZ , Edith JASNY , Benjamin PETSCH , Andreas THESS , Thomas SCHLAKE , Mariola FOTIN-MLECZEK , Regina HEIDENREICH , Sandra LAZZARO , Fatma DÖNER , Wolfgang GROSSE
IPC分类号： C07K14/005 , C07K14/205 , A61K39/145
CPC分类号： C12N15/00 , A61K39/12 , A61K2039/53 , C07K14/005 , C07K2319/00 , C12N2760/16122 , C12N2760/16134
摘要： The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.

29. 发明申请

US20170218030A1 RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE 审中-公开
公开(公告)号：US20170218030A1
公开(公告)日：2017-08-03
申请号：US15488815
申请日：2017-04-17
申请人： CureVac AG
发明人： Thomas KRAMPS , Margit SCHNEE , Daniel VOSS , Benjamin PETSCH
IPC分类号： C07K14/005 , C07K16/10 , C12N7/00 , A61K39/155
CPC分类号： C07K14/005 , A61K39/12 , A61K39/155 , A61K48/00 , A61K2039/505 , A61K2039/53 , A61K2039/6031 , C07K16/1027 , C07K2317/24 , C12N7/00 , C12N2760/18534
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

30. 发明申请

US20220395570A1 CORONAVIRUS VACCINE 有权
公开(公告)号：US20220395570A1
公开(公告)日：2022-12-15
申请号：US17818699
申请日：2022-08-09
申请人： CureVac AG
发明人： Susanne RAUCH , Hans Wolfgang GROßE , Benjamin PETSCH
IPC分类号： A61K39/215 , A61K9/00 , A61K47/26 , A61P31/14
摘要： The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式